Osteologie 2020; 29(01): 72-73
DOI: 10.1055/s-0039-3402889
© Georg Thieme Verlag KG Stuttgart · New YorkT-score as an Indicator of Fracture Risk on Therapy: Evidence From Romosozumab vs
Alendronate Treatment in the ARCH Trial
F Cosman
1
Columbia University, New York, NY, USA
,
E. Michael Lewiecki
2
New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA
,
Peter R. Ebeling
3
Monash University, Melbourne, Australia
,
E Hesse
4
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
,
N Napoli
5
Campus Bio-Medico University of Rome, Rome, Italy
,
Daria B. Crittenden
6
Amgen Inc., Thousand Oaks, CA, USA
,
M Rojeski
6
Amgen Inc., Thousand Oaks, CA, USA
,
W Yang
6
Amgen Inc., Thousand Oaks, CA, USA
,
C Libanati
7
UCB Pharma, Brussels, Belgium
,
S Ferrari
8
Geneva University Hospital, Geneva, Switzerland
› Institutsangaben
